about
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patientsPhase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response.Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 studyIntegrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.Internet use for health information among haematology outpatients: a cross-sectional survey.Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.High-dose daunorubicin in older patients with acute myeloid leukemia.Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients.PET and PET/CT for response evaluation in lymphoma: current practice and developments.The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder.
P50
Q27824793-851FFB88-D971-4562-9CAC-6A61D5BE0B63Q28209409-F67C2160-EC6B-4F5A-93DF-E8DAD8D82E93Q33385283-03CF07FF-DF46-45E5-9691-7FBDB950CF99Q33388853-2DE159D0-C64B-4E4A-A14D-80B5B6211F16Q33405150-B3329C62-049D-4688-AC18-0F2986BCD455Q33410306-C0E99DC0-1C11-41F9-9FCE-68AE35F8DBFBQ33420889-BD7B3BF7-B77C-456D-B058-BA617A450BFEQ33573355-ED3A736B-3E21-47B0-8EA2-6711AEE76B8EQ33707435-F6988EA4-7B63-4CB4-AE03-51D18B36ED00Q33816002-1A006A48-11C1-4BAB-A220-CE117DDCC536Q33945848-7FAB3425-6D28-44CC-AFC1-157789BB6A3DQ34183674-6B976180-686E-473C-8227-C9547663C93AQ34226292-EE96CE78-835D-4BA2-AA7D-8EE44B6BAE79Q34517305-4C56E5C9-0995-4EB7-B510-BA5288E4740EQ34612117-8E475B61-A526-44E3-A8D5-C6FA7E1CCC39Q35112648-1A8C0824-14BB-40A7-97CD-AC4DF3DDCF87Q36746441-78D6F2CD-D413-4BF4-B755-132BAD592EE5Q36805870-CE3431DE-F196-4B5E-97DB-C1601EC8FB69
P50
description
onderzoeker
@nl
name
Gregor Verhoef
@ast
Gregor Verhoef
@en
Gregor Verhoef
@es
Gregor Verhoef
@nl
Gregor Verhoef
@sl
type
label
Gregor Verhoef
@ast
Gregor Verhoef
@en
Gregor Verhoef
@es
Gregor Verhoef
@nl
Gregor Verhoef
@sl
prefLabel
Gregor Verhoef
@ast
Gregor Verhoef
@en
Gregor Verhoef
@es
Gregor Verhoef
@nl
Gregor Verhoef
@sl